Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2010-05-14
2011-12-20
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100, C424S142100, C424S144100, C514S885000
Reexamination Certificate
active
08080248
ABSTRACT:
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
REFERENCES:
patent: 5480796 (1996-01-01), Kishimoto
patent: 5670373 (1997-09-01), Kishimoto
patent: 5723120 (1998-03-01), Brakenhoff et al.
patent: 5795965 (1998-08-01), Tsuchiya et al.
patent: 5817790 (1998-10-01), Tsuchiya et al.
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6261560 (2001-07-01), Tsujinaka et al.
patent: 6410691 (2002-06-01), Kishimoto
patent: 6692742 (2004-02-01), Nakamura et al.
patent: 6723319 (2004-04-01), Ito et al.
patent: 7320792 (2008-01-01), Ito et al.
patent: 7479543 (2009-01-01), Tsuchiya et al.
patent: 7582298 (2009-09-01), Stevens et al.
patent: 2002/0187150 (2002-12-01), Mihara et al.
patent: 2004/0071706 (2004-04-01), Ito et al.
patent: 2004/0115197 (2004-06-01), Yoshizaki et al.
patent: 2004/0219156 (2004-11-01), Goldenberg et al.
patent: 2005/0142635 (2005-06-01), Tsuchiya et al.
patent: 2005/0238644 (2005-10-01), Mihara et al.
patent: 2006/0078531 (2006-04-01), Sota
patent: 2006/0078532 (2006-04-01), Omoigui
patent: 2006/0078533 (2006-04-01), Omoigui
patent: 2006/0177436 (2006-08-01), Ghilardi et al.
patent: 2006/0251653 (2006-11-01), Okuda et al.
patent: 2006/0275294 (2006-12-01), Omoigui
patent: 2006/0292147 (2006-12-01), Yoshizaki et al.
patent: 2007/0036785 (2007-02-01), Kishimoto et al.
patent: 2007/0036788 (2007-02-01), Sheriff et al.
patent: 2007/0098714 (2007-05-01), Nishimoto et al.
patent: 2007/0148169 (2007-06-01), Yoshizaki et al.
patent: 2007/0280945 (2007-12-01), Stevens et al.
patent: 2008/0124325 (2008-05-01), Ito et al.
patent: 2008/0145367 (2008-06-01), Bove et al.
patent: 0 628 639 (1994-12-01), None
patent: 0 409 607 (1996-10-01), None
patent: 0 783 893 (1997-07-01), None
patent: 0 800 829 (1997-10-01), None
patent: 0 811 384 (1997-12-01), None
patent: 0 628 639 (1999-06-01), None
patent: 0 923 941 (1999-06-01), None
patent: 1 004 315 (2000-05-01), None
patent: 1 074 268 (2001-02-01), None
patent: 1 108 435 (2001-06-01), None
patent: 1 314 437 (2003-05-01), None
patent: 1 327 681 (2003-07-01), None
patent: 1 334 731 (2003-08-01), None
patent: 1 475 100 (2004-11-01), None
patent: 1 475 101 (2004-11-01), None
patent: 0 413 908 (2005-08-01), None
patent: 0 923 941 (2006-05-01), None
patent: 0 811 384 (2006-06-01), None
patent: 1 108 435 (2007-01-01), None
patent: 1 810 980 (2007-07-01), None
patent: 1 074 268 (2008-01-01), None
patent: 1 334 731 (2008-02-01), None
patent: 1 004 315 (2008-05-01), None
patent: 2 694 767 (1994-02-01), None
patent: WO 95/09873 (1995-04-01), None
patent: WO 2004/096273 (2004-11-01), None
patent: WO 2005/028514 (2005-03-01), None
patent: WO 2007/143168 (2007-12-01), None
patent: WO 2008/020079 (2008-02-01), None
patent: WO 2008/049897 (2008-05-01), None
patent: WO 2008/145142 (2008-12-01), None
patent: WO 2009/095489 (2009-08-01), None
patent: WO 2009/109584 (2009-09-01), None
Mihara et al. (2005) “Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R . . . ” International Immunopharmacol. 5:1731-1740 (Elsevier, Netherlands).
Paul-Pletzer (2006) “Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy . . .” Drugs of Today 42(9):559-576 (Prous Science, Barcelona, Spain).
Chen Gang
Fairhurst Jeanette L.
Fandl James P.
Huang Tammy T.
Karow Margaret
Cottingham, Esq. Frank R.
Gregg, Esq. Valeta
Mertz Prema
Regeneron Pharmaceuticals Inc.
LandOfFree
Method of treating rheumatoid arthritis with an IL-6R antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating rheumatoid arthritis with an IL-6R antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating rheumatoid arthritis with an IL-6R antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314317